Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus/Eucreas) and Sitagliptin (Januvia/Janumet) After Two Weeks.
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2015
At a glance
- Drugs Vildagliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FPG-VISIT
- Sponsors Novartis; Novartis Pharma
- 19 Sep 2014 Primary endpoint has been met (Fasting plasma glucose level after 14 days of treatment with vildagliptin is superior to sitagliptin), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 23 Jul 2011 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History